Save on Anifrolumab-FNIA with Coupons, Discounts & Savings Programs

Anifrolumab-FNIA is available in a 300 mg/2 mL (150 mg/mL) in a single-dose vial.

Anifrolumab-FNIA is a biologic medication that is used as an add-on therapy for moderate-to-severe systemic lupus erythematosus (SLE).

Anifrolumab-FNIA is a biologic medication. It attaches to certain proteins in your immune system that play a role in SLE. By attaching to these proteins, it stops them from turning on and blocks inflammatory pathways in your body.

The typical dose of Anifrolumab-FNIA is 300 mg injected into the veins (IV) once every month. It’s given as an infusion over 30 minutes.

Anifrolumab-FNIA is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Anifrolumab-FNIA:

• Upper respiratory infection
• Bronchitis
• Infusion-related reactions (headache, dizziness, nausea)
• Herpes zoster infection (shingles)
• Cough

Serious side effects are rare with Anifrolumab-FNIA. Contact your healthcare provider immediately if you experience any of the following.

Severe infection: confusion, fever, difficulty breathing, weakness, cough, sweating, chills, stomach pain, diarrhea, burning sensation when you urinate
Serious allergic reaction (anaphylaxis): difficulty breathing, tightness in the throat, hives, itching, fast heartbeat, nausea, dizziness, lightheadedness, swelling in the face or tongue

There are no major drug interactions listed for Anifrolumab-FNIA. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

It is not known if Anifrolumab-FNIA will harm your unborn baby. Tell your healthcare provider
if you are pregnant, think you might be pregnant, or plan to become pregnant during your treatment with Anifrolumab-FNIA.
If you become pregnant while receiving Anifrolumab-FNIA, talk to your healthcare provider.
A pregnancy exposure registry monitors pregnancy outcomes in women exposed to Anifrolumab-FNIA. You can find out more
information about the registry by calling AstraZeneca at 1-877-693-9268.

• Saphnelo